Pharma Commercial Strategy Playbook: Five Plays That Still Work
The five pharma commercial strategy plays we still see working in 2026, with the failure mode each one is designed to prevent.
Play 1 — Launch sequencing built backwards from access
Most launches sequence around the PDUFA date. Winning launches sequence backwards from formulary decisions and value committee meetings, then pull all field, medical, and marketing milestones into that calendar.
Play 2 — KOL stratification by influence, not title
Tier KOLs by category-shaping influence (publications, guideline involvement, peer reach), not by institutional prestige. The Chief of Cardiology at a brand-name hospital may move the market less than a high-volume community cardiologist with a podcast.
Play 3 — Payer narrative before the launch deck
Build the AMCP dossier and budget-impact model before the brand campaign. Field access teams should be carrying a one-page payer story 90 days before approval.
Play 4 — Omnichannel HCP, run as one team
Field, NPP, congress, email, and paid social belong on one weekly stand-up. The metric is not channel-by-channel reach; it is HCP journey progression — share-of-script intent moving stage by stage.
Play 5 — Real-world evidence as a continuous release
Pre-launch RWE plans, post-launch registries, and HEOR publications are the substrate everything else runs on. Treat them like a product roadmap with quarterly releases.
How to use this
Score your brand against each play on a 1-5 scale. Anything below a 3 deserves a 90-day intervention. We embed with commercial leadership teams to do exactly this — see the Trust API framework for how we structure those engagements.
Ready to put this into practice?
We embed with HealthTech, pharma, and medical device commercial teams as growth partners — not consultants. Start with a 10-minute Trust Audit or book a discovery call.